Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Rosuvastatin calcium

Abstract

Rosuvastatin calcium (Crestor; AstraZeneca), the seventh drug in the statin class, was approved by the US FDA in August 2003 for the reduction of cholesterol levels in patients with hypercholesterolaemia. Billed as the most potent statin available, can it overcome initial setbacks and make a significant impact in the multi-billion-dollar market for cholesterol-lowering drugs?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Rosuvastatin calcium.
Figure 2: Market for drugs to treat dyslipidaemia in US $ billion.

References

  1. 1

    Tobert, J. A. Lovastatin and beyond: the history of the 1HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517–526 (2003).

    CAS  Article  Google Scholar 

  2. 2

    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360, 7–22 (2002).

  3. 3

    Sever, P. S. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).

    CAS  Article  Google Scholar 

  4. 4

    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).

  5. 5

    Watanabe, M. et al. Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptonates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem. 5, 437–444 (1997).

    CAS  Article  Google Scholar 

  6. 6

    FDA Drug Approvals List [online] (cited 26 Aug 2003). <http://www.fda.gov/cder/foi/label/2003/21366_crestor_lbl.pdf> (2003).

  7. 7

    Jones, P. H. et al. for the STELLAR study group. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein cholesterol and high density lipoprotein cholesterol results. J. Am. Coll. Cardiol. 92, 152–160 (2003).

    CAS  Article  Google Scholar 

  8. 8

    Earl, J. & Kirkpatrick, P. Ezetimibe. Nature Rev. Drug Discov. 2, 97–98 (2003).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jeremy Quirk.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Quirk, J., Thornton, M. & Kirkpatrick, P. Rosuvastatin calcium. Nat Rev Drug Discov 2, 769–770 (2003). https://doi.org/10.1038/nrd1205

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing